Organic Acids
Medchemexpress LLC LL-37 amide (TFA) | 99.34% | 4492.28 | 5 MG
LL-37 amide TFA is a selective agonist of formyl peptide receptor-like FPRL1, effectively inhibiting periodontal pathogens. It exerts bactericidal effects by activating immune cell chemotaxis and disrupting bacterial cell membrane integrity. This peptide also regulates inflammatory responses and promotes angiogenesis. Its amidation modification reduces sensitivity to serum inhibition and improves stability, making it suitable for research on infection-related diseases like periodontal disease, deep tissue injuries, and wound healing.
- Selective agonist of formyl peptide receptor-like FPRL1
- Inhibits periodontal pathogens
- Exerts bactericidal effects
- Regulates inflammatory responses
- Promotes angiogenesis
- Improved stability and resistance to enzymatic degradation
- Useful in research for infection-related diseases and wound healing
- Effective against Gram-positive and Gram-negative bacteria
Medchemexpress LLC Alvespimycin trifluoroacetate | 00-00-0 | MFCD08457919 | 99.0% | 730.77 g/mol | C34H49F3N4O10 | 1 MG
Alvespimycin TFA is the trifluoroacetate salt of 17-DMAG, a small-molecule Hsp90 inhibitor used in research to probe Hsp90 biology, induce client protein degradation, and trigger stress responses in cancer cell models.
- Potent Hsp90 inhibition with low-nanomolar cellular activity.
- Promotes degradation of Hsp90 client proteins, including Her2.
- Induces Hsp70 expression and apoptosis in sensitive cancer cells.
- High purity solid suitable for biochemical and cellular assays.
- Available in small research quantities for dose-response studies.
- Stable when stored sealed at recommended temperatures.
Medchemexpress LLC BIM 23042 (trifluoroacetate) | 00-00-0 | MFCD32666112 | 96.2% | 1192.45 g/mol | C63H73N11O9S2·xC2HF3O2 | 1 MG
BIM 23042 (trifluoroacetate) is a somatostatin-like octapeptide analogue that acts as a selective neuromedin B receptor (NMB-R/BB1) antagonist. It is supplied as the trifluoroacetate salt in solid form for research use in receptor pharmacology and intracellular calcium signaling studies.
- Selective neuromedin B receptor (NMB-R/BB1) antagonist.
- Somatostatin-like octapeptide structure as the trifluoroacetate salt.
- Purity approximately 96.2% by supplier analysis.
- White to off-white solid powder suitable for laboratory use.
- Store sealed away from moisture and light; powder stable at -80°C (2 years) or -20°C (1 year).
Medchemexpress LLC AS-99 TFA | 99.2% | C29H31F6N5O5S2 | 1 ML
AS-99 TFA is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor with anti-leukemic activity. It blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo. The compound has an IC50 of 0.79 μM and a Kd of 0.89 μM for ASH1L.
- First-in-class, potent, and selective ASH1L histone methyltransferase inhibitor.
- Exhibits anti-leukemic activity.
- Blocks cell proliferation.
- Induces apoptosis and differentiation.
- Downregulates MLL fusion target genes.
- Reduces leukemia burden in vivo.
- Selective for ASH1L, with no significant inhibition observed at 50 μM on a panel of 20 other histone methyltransferases.
Apexbio Technology LLC cyclo(RLsKDK) TFA(Synonyms: cyclo(RLsKDK), Cyclic peptide RLsKDK, ADAM8 inhibitor peptide, Cyclo-Arg-Leu-Ser-Lys-Asp-Lys), 1mg.
Cyclo(RLsKDK) TFA is a cyclic pentapeptide inhibitor targeting the metalloproteinase ADAM8 a transmembrane protein frequently dysregulated in pathological conditions such as inflammation cancer and neurodegenerative diseases By specifically inhibiting ADAM8 enzymatic activity cyclo(RLsKDK) TFA may modulate disease-associated cellular processes This molecule holds promise as a research tool for studying ADAM8 function and as a potential therapeutic candidate in inflammatory disorders and oncology
Medchemexpress LLC Nangibotide TFA | 2014384-91-7 | 99.4% | 1457.46 | 25 MG
Nangibotide TFA | 2014384-91-7 | 99.4% | 1457.46 | 25 MG